gene, 21, 23 genetic ancestry, 24, 25 or linkage studies, 26 often focusing on subclinical measures other than CIMT. 24, 27 Mixed genetic ancestry contributes to variable disease risk for common complex diseases among admixed populations. Traditional genetic association studies control for population stratification, which may be sufficient to account for global ancestry among homogenous populations but not among admixed populations. 28 Recent studies have proposed the inclusion of local ancestry in addition to global ancestry to account for population substructure in association studies. 29, 30 The authors noted that local and global ancestry estimates are different, and only the first of the local and global principal components are moderately correlated, showing that there would be lower falsepositive associations if both local and global ancestry were used. Admixture mapping allows the detection of variants with excess local ancestry associated with a particular disease/trait, the variants assumed to be inherited from the ancestral population with a higher prevalence of that disease. 31, 32 Furthermore, admixture mapping makes use of a dense set of markers thereby increasing the likelihood of detecting shorter ancestry segments and ancestry switches in the genome. 32 To date, only one study examining the association of global ancestry with CIMT has reported a significant association of European ancestry with lower common CIMT. 24, 25 Moreover, local ancestry association with cardiovascular events has not yet been examined. Therefore, in the current study, we evaluated the association of local European ancestry (LEA), estimated using genome-wide single-nucleotide polymorphism (SNP) data, with cCIMT among African Americans from the MESA (Multi-Ethnic Study of Atherosclerosis). We also conducted replication of the significant LEA-cCIMT associations found in MESA with cCIMT in the ARIC cohort (Atherosclerosis Risk in Communities). Furthermore, we tested the associations of LEA regions significantly associated with cCIMT with clinical cardiovascular events in the MESA cohort.
Methods

Study Population
MESA is a population-based prospective cohort study that started in 2000. The study has been described in detail elsewhere. 33 Briefly, MESA was designed to characterize subclinical CVD and ascertain factors involved in the progression of subclinical to clinical CVD. The study enrolled men and women, aged 45 to 84 years, without prevalent CVD, across 6 study sites. African Americans comprised 28% (n=1891) of the total number of participants enrolled during baseline. In the current study, a total of 1554 African Americans who provided consent and had complete information on genomic data, cCIMT, and CVD risk factors were included.
ARIC is a prospective cohort study that began in 1987 and included cohort and community surveillance components and a study design similar to MESA. 34 Participants representative of their respective communities were recruited from 4 field centers. A greater proportion of the African Americans were recruited from Jackson, MS, and comprised 27% (n=4314) of the total number of cohort participants at baseline. In the current study, a total of 3000 African Americans without prevalent CVD and with complete information on sociodemographic, lifestyle, clinical, and genomic data were included.
Data Collection and Clinical Examination
The baseline examination in MESA included standardized questionnaires on demographic, lifestyle, socioeconomic, and clinical factors. Data on medication use was collected via a medication inventory. In addition, anthropometric measures such as weight and height; physiological measures such as blood pressure; laboratory measures such as high-density lipoprotein (HDL) cholesterol; and the subclinical measures of CVD using carotid ultrasound, computed tomography, or magnetic resonance imaging were obtained. 33 Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or antihypertensive medication use; diabetes mellitus was defined based on medication use or fasting plasma glucose of ≥126 mg/dL, and low-density lipoprotein (LDL) and HDL cholesterol (mg/ dL) were measured and calculated from fasting blood samples. 35 The baseline examination in ARIC included a home interview and a clinical examination. 34 The interview collected information on the participant's medical/family history including hospitalizations in the past year and other lifestyle, and socioeconomic factors. The clinic visit included procedures such as anthropometry and physical examination, sitting blood pressure, obtaining blood samples for hematology and lipid profile, medical history and record review, echocardiography, and ultrasound. Classification of CVD-related risk factors were the same as those described above for the MESA cohort. Follow-up included examinations every 3 years, annual phone interviews to document overall health and event status, and surveillance for hospitalized and nonhospitalized events and deaths.
Common CIMT Measurement
Both MESA and ARIC used comparable methods for the measurement of cCIMT. The details of the ultrasound method used to measure cCIMT in the MESA cohort have been previously described. 15 To summarize, trained technicians at each field center used high-resolution B-mode ultrasound to measure CIMT using a standardized protocol. The procedure included a single longitudinal lateral view of the distal 10 mm of the common carotid artery with measurements taken for both the right and left arteries, including the far and near walls. Between-reader correlation coefficients were 0.84 and 0.86, for 66 and 48 blinded replicate readings of the CIMT by 2 readers, respectively. In the current analysis, we used the values for the mean of the maximal cCIMT as the phenotype, which has been log 10 transformed to achieve normality.
The details of the B-mode ultrasound method used to measure cCIMT in the ARIC cohort have been described elsewhere. 36, 37 Briefly, a standardized protocol was used across all field centers, and measurements were taken at a central ultrasound-reading center using the Biosound 2000IIsa model (Indianapolis, IN). The site-specific reliability coefficients were estimated to be 0.77, 0.73, and 0.70 for mean carotid far-wall IMT at the carotid bifurcation and the internal and common carotid arteries, respectively. CIMT measurements for the common carotid segment were obtained 1 cm proximal to the dilatation of the carotid bulb. Both the right and left arteries were measured, involving 11 contiguous measurements on each side. The cCIMT was also measured for both the near and far walls from 3 different angles to obtain the maximum wall thickness. Measurements averaged across the near-far walls and the right-left arteries were used to calculate maximal cCIMT and log 10 transformed for analysis in the current study.
Clinical Outcomes
Incident events were determined over an average follow-up of 9.3 years from baseline through December 31, 2013 in the MESA cohort. Event information was obtained through phone interviews of participants/family members and medical record reviews at 9-to 12-month intervals. Two physicians reviewed the records separately for independent end point classification and assignment of incidence dates with further adjudication of the records by the entire review committee in case of disagreements. CVD-related deaths were assigned after identification and review by a committee. The causes for non-CVD deaths were obtained through state or city vital statistics departments or the National Death Index.
Myocardial infarction (MI) was identified based on a combination of symptoms, ECG, and cardiac biomarker levels. Hard CHD consisted of MI, resuscitated cardiac arrest, and fatal CHD. Resuscitated cardiac arrest included complete recovery of a patient from a full cardiac arrest using cardiopulmonary resuscitation (including cardioversion). Fatal CHD was defined as death ≤28 days of an MI, chest pain ≤72 hours of death, or history of CHD if the cause of death was unknown. All CHD was a composite of angina and the hard CHD components. Angina was defined as the presence of typical chest pain or atypical symptoms and one of the following: coronary artery bypass graft surgery or other revascularization procedures, obstruction of ≥70% on coronary angiography, or ischemia on stress tests/resting ECG.
Stroke included a documented focal neurological deficit of rapid onset that lasted ≥24 hours or until death; or a clinically relevant lesion on brain imaging if the deficit lasted <24 hours. Focal neurological deficits because of nonvascular causes such as brain trauma, tumor, or infection were excluded. Hard CVD included a composite of hard CHD and stroke and stroke-related deaths. All CVD included hard CVD and atherosclerotic or CVD risk-related deaths other than MI or stroke.
Genotyping and Quality Control
Participants from both cohorts who consented for genetic analysis and provided DNA samples were genotyped using the Affymetrix 6.0 SNP array at the Broad Institute Center for Genotyping and Analysis according to the manufacturer's protocol. 38 The 1554 African Americans from MESA and 3000 African Americans from ARIC included in the current study were genotyped for 909 622 SNPs, of which 878 614 were autosomal in the MESA cohort and 841 820 in the ARIC cohort. Relatedness between participants in each cohort was assessed using the KING software. 39 
Estimation of LEA
We used the Local Ancestry inference in adMixed Populations using Linkage Disequilibrium (LAMP-LD) method to determine LEA in both cohorts. 40 It incorporates a dense set of markers to ascertain ancestry at each SNP for each individual based on haplotype sets from ancestral populations. We used the HapMap phase II and III data from 234 Utah residents with North-West European ancestry (CEU) and 230 Yorubans (YRI) from Ibadan, Nigeria with African ancestry to serve as our reference populations (HapMap phase III, release 2). The reference haplotype data were used to determine parameters for the Hidden Markov Model with 15 state spaces. The local ancestry was estimated using the Hidden Markov Model parameters within a 300 SNPs long window-based framework. Each chromosome was analyzed separately, and the local ancestry coded as the number of European ancestry alleles at each SNP (ie, 0, 1, or 2 where 0 means both chromosomal regions had African ancestry, 1 means the chromosomal region is admixed, meaning one was European ancestry and one was African ancestry, and 2 means both chromosomal regions had European ancestry). Global ancestry was calculated from local ancestry by averaging it across all chromosomes for each individual.
A SNP most significantly associated with cCIMT along with the block of neighboring SNPs with similar number of European ancestry (0, 1, or 2) were denoted as a LEA region. Additionally, blocks of same ancestry LEA regions were further defined based on whether the SNPs were in the genic or intergenic regions. A genic region included the 5′ and 3′ untranslated regions, the exons, and the introns; the intergenic regions were those that fell between 2 genic regions as described above. Gene nomenclatures were obtained from the National Center for Biotechnology Information's Reference Sequence database.
Additionally, for the statistically significant SNPs, the proportion of European ancestry (PEA) was estimated in both MESA and ARIC studies separately.
The institutional review board at the University of Alabama at Birmingham approved this study and the use of deidentified data obtained from both the MESA and ARIC studies.
Association With cCIMT
Ancestry association with cCIMT was tested using the PLINK (version 1.9) software with default settings. 41 We used an additive linear regression model to evaluate the LEA association at 611 449 SNPs by coding ancestry at one SNP as homozygous European (11), heterozygous European/African (12), or homozygous African (22) , the latter being used as the reference. We adjusted for global ancestry and other known CVD risk factors including age, sex, current smoking status, hypertension and hypertension medications, diabetes mellitus, and LDL and HDL cholesterol. To correct for multiple testing, we calculated the total number of effective independent tests based on a method proposed by Shriner et al. 42 Briefly, the method is based on the concept that adjacent SNPs would show high correlation as opposed to distant ones. The effective number of tests was estimated from 611 449 SNPs by fitting an autoregressive model to the additively coded ancestry. Because ancestry tends to be highly correlated over longer regions of the chromosome as opposed to genotype data, the number of independent tests estimated is small despite the inclusion of genome-wide level ancestry data in the model. On the basis of this approach, the total number of independent tests in our analyses was 148.6, resulting in a threshold significance level of 3.36×10 −4 .
Replication of Significant cCIMT-LEA Associations in the ARIC Cohort
All LEA regions associated with cCIMT (P<0.05) in MESA were examined for replication within the ARIC cohort and determined if the magnitude and direction of association observed are similar in both cohorts. Similar to MESA, we adjusted for global ancestry, age, sex, current smoking status, hypertension and hypertension medications, diabetes mellitus, and LDL and HDL cholesterol in the model.
Association With Clinical Events
LEA regions associated with cCIMT (P<0.05) were also evaluated for associations with MI, stroke, hard CHD, all CHD, hard CVD, and all CVD events in the MESA cohort. Known CVD risk factors and global ancestry were adjusted for in multivariable logistic regression models in PLINK (v1.9).
LEA Regions Including Previously Reported CIMT SNPs
On the basis of previous CIMT-genetic association studies that included either SNPs or ancestry informative markers (AIMs) used to estimate global ancestry, we identified 595 markers. Of these, 181 SNPs were based on a combination of candidate gene, genome-wide association studies (GWAS) or meta-analysis studies, 191 SNPs were obtained from a GWAS conducted by Melton et al, 22 and the remaining were 24 and 199 AIMs used by Reiner et al 43 and Wassel et al, 24 respectively, in their analysis of global ancestry association with CIMT. We assessed the LEA regions that contained these SNPs or AIMS and report the associations of those significant at P<0.05 in our cCIMT analysis.
Results
The characteristics of the MESA and ARIC African Americans included in the current analysis are shown in Table 2 with the remaining significant (P<0.05) regions presented in Table II in the Data Supplement. The LEA region that achieved genome-wide significance was observed in the intronic region on chromosome 11, in the SERGEF gene (secretion-regulating guanine nucleotide exchange factor; β=0.0137; P=2.98×10 ; PEA=23.2%). Replication of LEA regions associated with cCIMT (P<0.05) in the MESA cohort and found significantly associated with cCIMT in ARIC are presented in Table 3 for the top 5 hits and in Table III Table 4 Table 2 were associated with stroke (Table IV in ; PEA=22.2%). Likewise, the ) with the RASGRF2 gene (Ras protein-specific guanine nucleotidereleasing factor 2) region on chromosome 5. The LEA regions in CKMT2 and RASGRF2 (PEA=20.4% for both) were significantly associated with all events except for stroke.
Regions of LEA associated with cCIMT at previously significant SNPs are shown in Table 5 . A total of 131 SNPs and AIMs were available in our GWAS data set, of which LEA regions that included 5 of these SNPs were significant at P<0.05. The strongest LEA association was observed on chromosome 5 with rs2081015 in the coding region of the GALNT10 gene (polypeptide N-acetyl galactosaminyltransferase 10; β=−0.0118; 
P=2.45×10
Discussion
The association of local ancestry with cCIMT as a measure of subclinical atherosclerosis has not yet been evaluated. Our study is the first to report LEA associations with cCIMT among African Americans using a genome-wide admixture mapping method. We detected several LEA regions significantly associated with cCIMT, with one reaching genome-wide significance. We were also able to replicate 127 LEA regions associated with cCIMT in the ARIC cohort; however, we could not replicate the genome-wide significant association of the LEA region in SERGEF with cCIMT. Some of the LEA regions associated with cCIMT were also significantly associated with several clinical CVD events in MESA, with the top cCIMT hit being associated with stroke. Most of the LEA regions showed a protective association in relation to the clinical events except in case of stroke. Additionally, the magnitude of associations observed for clinical CVD events in our study are stronger Figure. Manhattan plot of the association between local European ancestry (LEA) and common carotid artery intima-media thickness using the additive model (adjusting for global ancestry, age, sex, current smoking status, hypertension and hypertension medications, diabetes mellitus, and low-density lipoprotein and high-density lipoprotein cholesterol). The gray line corresponds to P=3.36×10 −4 based on the effective number of independent tests, and the results above this threshold are considered statistically significant associations. (Negative log 10 P values are plotted against each single-nucleotide polymorphism's respective position on each chromosome). Admixture Mapping and Cardiovascular Disease compared to some of the previously reported genetic association studies on CVD events/traits. 44, 45 Finally, we also present SNPs from previous studies that were significantly associated with cCIMT in the current study.
Earlier studies have examined global ancestry associations with subclinical CVD, of which only one study showed that a one standard deviation increase in global European ancestry was statistically significantly associated with a 2% lower cCIMT among African Americans from MESA. 24 Between two other studies that examined global ancestry and cCIMT, only one reported a 1.1% statistically nonsignificant decrease in cCIMT after adjusting for CVD risk factors. 25 However, these studies were based on a small set of AIMs and were therefore limited in their ability to detect excess ancestry that may fall in regions in-between AIMs. Our research expands upon these studies by exploring local ancestry after adjusting for global ancestry proportions to discover novel associations in relation to cCIMT using a genome-wide admixture mapping approach.
The genome-wide significant LEA region associated with cCIMT was located on chromosome 11p14 in the SERGEF gene that encodes for the SERGEF/deafness locus putative guanine nucleotide exchange factor (DelGEF) protein. It is a homolog of the Ras-related GEF (Ran) for guanosine-triphosphatase (GTPase) and is present in almost all human tissues. 46 The function of this gene is not yet known but it has a potential readthrough transcript with the TPH1 gene. Therefore, transcripts of the SERGEF gene may potentially encode for TPH1 as well, a protein that is involved in the synthesis of serotonin (5-HT) -a neurotransmitter that has also been implicated in mediating immune responses. 47 Serotonin binding with GTPases was
shown to mediate platelet function resulting in a prothrombotic state that was associated with cortical strokes in a case-control study. 48, 49 Serotonin present in different immune cells was shown to regulate varied functions such as facilitating chemotaxis, phagocytosis, and inducing the release of pro-and anti-inflammatory cells through specific 5-HT receptors. 50, 51 Serotonin also modulates vascular tone by increasing the proliferation, migration and constriction of vascular smooth muscle cells and may potentially play a role in atherosclerosis or stroke by mediating immune and vascular smooth muscle cell responses. 52 Among the replicated gene regions, CADPS was most significantly associated with cCIMT in the ARIC cohort. This gene encodes for the CADPS/CAPS1 membrane protein that facilitates neurotransmitter release from secretory vesicles. 53 This is only one of the few proteins that shows specificity to the dense core vesicles (DCV) and aids the release of norepinephrine in a adenosine triphosphate (ATP) primed and Ca 2+ -dependent manner. CADPS was shown to interact with a new Ras-like protein in cardiomyocytes and regulate the secretion of atrial natriuretic peptide (ANP). 54 ANP has been shown to regulate blood pressure and prevent hypertrophy and fibrosis of the myocardium. Plasma ANP levels have been correlated with CVD events and death. 55 Therefore, CADPS can be hypothesized to play a role in subclinical or clinical CVD.
SNPs within the LRRC3B gene have been associated with cholesterol, rs4973800 specifically being associated with LDL cholesterol, whereas rs955027 was associated with calcium levels in the National Heart, Lung, and Blood Institute's (NHLBI) FamHS (Family Heart Study). This gene interacts with the (ligand of Numb protein X 1) LNX1 gene. LNX1 binds the Numb The PRMT3 gene belongs to the protein arginine methyltransferase family and is involved in the synthesis of asymmetric dimethylarginine (ADMA). Alternatively, increasing concentrations of ADMA in coronary artery endothelial cells were shown to increase the expression of the PRMT3 gene, confirmed by increase in the levels of PRMT3 mRNA and protein levels both in vitro and in vivo. 58 ADMA is found in several vascular tissues and has been associated with risk factors of CVD and clinical CVD. 58, 59 ADMA is known to inhibit NO synthase resulting in endothelial dysfunction thereby increasing the risk of atherosclerosis. The association of stroke with PRMT3 in our study further supports the role of this gene in CVD. Additionally, a protein interactome of the human PRMTs mapped using yeast 2-hybrid sequencing reported direct interaction of SERGEF and indirect interaction of LNX1 with PRMT6. 60 This report supports the hypothesis that the top genes observed in our study may be part of one or more interacting biological pathways that result in the pathogenesis of CVD.
Hard and all CHD were associated with the LHFPL2 gene, which is part of the superfamily of tetraspan transmembrane protein-encoding genes. Few genetic studies have reported complex disease/trait associations with this gene. The most relevant of these is the association of rs341930 with MI among African Americans from NHLBI's STAMPEED project (SNP Typing for Association with Multiple Phenotypes from Existing Epidemiological Data), a substudy of the Cardiovascular Health Study cohort, and rs2029905 (LHFPL2 and ARSB [arylsulfate B]) with systolic blood pressure in NHLBI's FamHS (NHGRI's GWAS catalog). Although the function of this gene has not yet been elucidated, differential expression of the gene or transcripts has been associated with myocardial repair, 61 inflammatory response through macrophages, 62 and new collagen formation. 63 Thus, the gene may be part of one or more pathways that contribute to the development of CHD.
The cCIMT-associated LEA regions in CKMT2 and RASGRF2 genes were significantly associated with all clinical events except stroke. The CKMT2 gene encodes the sMtCK (sarcomeric mitochondrial creatine kinase), an isoenzyme of the CK family that also includes the cytosolic enzymes-CK-MM (muscle), CK-BB (brain), and CK-MB (heart). 64 sMtCK is present in the intermembrane space of the mitochondria and is commonly expressed in striated and cardiac muscles. 65 It is involved in high energy metabolism, providing ATP through rapid regeneration of creatine phosphate to calcium or myosin ATPases for processes such as vascular remodeling. 66 Serum CK levels, and CK-MB more specifically, have been used to determine myocardial injury, but they have also been associated with blood pressure among individuals of African ancestry, showing higher serum CK levels and higher CK activity in the tissues. 66 The higher CK activity is hypothesized to increase vascular contractility and blood pressure, leading to CVD among these individuals. Thus, the role of CK in CVD-related risk factors and progression to disease is well substantiated but needs further evaluation among African Americans, especially for CKMT2.
The RASGRF2 gene encodes the GEF associated with calmodulin and has been shown to activate the mitogenactivated protein kinase (MAPK) pathway by initiating GTP binding to Ras-and Rac-GTPases. 67 The MAPK pathway is involved in signal transduction resulting in several processes such as cell growth, proliferation, and inflammation. RASGRF2 was also shown to mediate the stimulation of nuclear factoractivated T cells in conjunction with T-cell receptor, Vav1, and calcium-dependent pathways. 67 SNPs in the gene have been associated with body weight measures (rs6869328) and magnesium (Mg 2+ ) levels (rs2592093 [NHGRI's GWAS catalog]). 68 Mg 2+ has been shown to regulate blood pressure, and lower levels have been shown to result in vascular changes such as endothelial dysfunction, inflammation, and vascular remodeling. 69 The RASGRF2 may, therefore, play a role in the inflammatory response associated with CVD.
Among the LEA regions that included SNPs previously associated with CIMT, the strongest association was noted for the region including rs2081015 in the GALNT10 gene mapped to chromosomes 5, the LEA at the SNP being associated with a 2.7% lower cCIMT. However, the GALNT10 SNP was shown to be associated with higher cCIMT, specifically among men, in a recent genome-wide sex interaction study among subjects from the Northern Manhattan Study cohort. 70 The gene also includes a novel top-hit associated with body mass index from a meta-analysis among individuals with African ancestry 71 LEA at the gene region including rs9847748 within the FAM19A4 gene was associated with a 2.5% lower cCIMT. The protein encoded by the FAM19A4 gene was recently revealed to be a novel cytokine with a potential role in the migration and activation of macrophages on inflammatory stimulation and could, therefore, be involved in atherogenesis as well. 72 Our study has some strengths and limitations. There are several software programs available for ancestry estimation; however, it has been suggested that LAMP-LD is currently the most accurate software available to estimate local ancestry inference among unrelated individuals. 40, 73 This provides higher resolution for ancestry switches and allows detection of smaller local ancestry regions. We acknowledge that despite the availability of a dense set of markers, we were limited by the use of a predefined set of GWAS SNPs and the subsequent loss during quality control. This may have resulted in gene regions that were not comprehensively covered and so associations in these regions may have been missed-either those that were reported previously or novel ones. However, this approach still provides higher power than previous studies that relied on the use of AIMs, which are only localized to certain genomic regions. Shriner et al 32 estimated that <200 000 random markers are sufficient to determine ancestry based on linkage disequilibrium among African Americans. In both our cohorts, we used ≈600 000 SNPs to estimate LEA and therefore had sufficient coverage to estimate ancestry associations with cCIMT. Previous genetic studies have lacked variations specific to admixed populations or the statistical power to detect low-frequency alleles observed in these populations. The use of admixture analysis in the current study facilitated the discovery of novel gene regions associated with cCIMT among African Americans. Although we adjusted for the commonly known risk factors for CVD, residual confounding may still be present. The proportion of European Ancestry both globally and locally at most regions seemed to be higher in MESA than in ARIC, suggesting slightly different admixed populations; however, the proportions are still large enough that we do not anticipate major issues with the admixture mapping approach. The current analysis is based on cross-sectional measurements of cCIMT and therefore cannot be applied to progression of CIMT to incident CVD events. However, we were able to replicate the LEA-cCIMT association in another cohort and report several cCIMT-associated LEA regions that are also associated with clinical CVD events, which provides support to the hypothesis that common gene pathways regulate both atherosclerosis and manifest CVD.
This study is the first to report the association of LEA in relation to cCIMT using a genome-wide admixture mapping approach among African Americans from a large populationbased cohort. More importantly, we were able to replicate the association of several LEA regions with cCIMT in the ARIC cohort. We also report a subset of these LEA regions to be associated with various clinical CVD events in MESA. CIMT as a subclinical measure can indicate progress to different CVD-related events, and we observe such results in our study. However, future studies are needed to evaluate functional associations that would aid the search for the true causal variants associated with cCIMT and CVD.
